Table I.
Univariate analyses of the quality of amplification associated with clinicopathological characteristics and a number of suppressive factors.
| High | Low | |||
|---|---|---|---|---|
| Clinicopathological characteristic | n (%) | n (%) | χ2 | P-value |
| Sex | 0.232 | 0.656 | ||
| Male | 15 (44.4) | 28 (53.8) | ||
| Female | 16 (51.6) | 24 (46.2) | ||
| BCLC stage | 22.270 | <0.001 | ||
| A | 24 (77.4) | 13 (25.0) | ||
| B | 5 (16.1) | 19 (36.5) | ||
| C | 2 (6.2) | 20 (38.5) | ||
| Tumor size, cm | 7.574 | 0.007 | ||
| >5 | 10 (32.3) | 33 (63.5) | ||
| ≤5 | 21 (67.7) | 19 (36.5) | ||
| Tumor number | 4.310 | 0.044 | ||
| 1 | 21 (67.7) | 23 (44.2) | ||
| ≥2 | 10 (32.3) | 29 (55.8) | ||
| DOD, months | 16.929 | <0.001 | ||
| ≥20 | 24 (77.4) | 16 (30.8) | ||
| <20 | 7 (22.6) | 36 (69.2) | ||
| TBIL, µmol/l | 0.361 | 0.646 | ||
| ≥17.1 | 17 (54.8) | 32 (61.5) | ||
| <17.1 | 14 (45.2) | 20 (38.5) | ||
| AFP, ng/ml | 19.136 | <0.001 | ||
| ≤20 | 23 (74.2) | 13 (25.0) | ||
| >20 | 8 (25.8) | 39 (75.0) | ||
| Albumin, g/l | 3.832 | 0.041 | ||
| ≥55 | 20 (64.5) | 22 (42.3) | ||
| <55 | 11 (35.5) | 30 (57.7) | ||
| Ascites | 0.066 | 0.824 | ||
| Yes | 17 (54.8) | 27 (51.9) | ||
| No | 14 (45.2) | 25 (48.1) | ||
| TACE | 1.745 | 0.263 | ||
| Yes | 4 (12.9) | 13 (25.0) | ||
| No | 27 (87.1) | 39 (75.0) | ||
| ALT, U/l | 0.148 | 0.819 | ||
| ≥40 | 15 (48.4) | 22 (42.3) | ||
| <40 | 16 (51.6) | 30 (57.7) | ||
| AST, U/l | 0.086 | 0.819 | ||
| ≥40 | 12 (38.7) | 21 (40.4) | ||
| <40 | 19 (61.3) | 31 (59.6) | ||
| PT, sec | 0.001 | 0.998 | ||
| ≥14 | 15 (48.4) | 24 (46.2) | ||
| <14 | 16 (51.6) | 28 (53.8) | ||
| Tregs, % | 17.566 | <0.001 | ||
| <0.91±0.54 | 23 (74.2) | 14 (26.9) | ||
| ≥0.91±0.54 | 8 (25.8) | 38 (73.1) | ||
| γδ T17 cells, % | 7.961 | 0.006 | ||
| <0.68±0.17 | 20 (64.5) | 17 (32.7) | ||
| ≥0.68±0.17 | 11 (35.5) | 35 (67.3) | ||
| Age, years | 0.021 | 0.989 | ||
| <40 | 1 (3.2) | 2 (3.8) | ||
| 40–55 | 12 (38.7) | 20 (38.5) | ||
| 55< | 18 (58.1) | 30 (57.7) | ||
BCLC, Barcelona-Clinic Liver Cancer; DOD, duration of disease; TBIL, totalbilirubin; AFP, α-fetoprotein; TACE, transarterial chemoembolization; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; Tregs, regulatory T cells.